Orthofix Medical Inc. — Q2 2022 Form 10-Q
Business and period. Orthofix is a global medical-device company focused on spine and orthopedics, selling in more than 60 countries. This unaudited report covers the three and six months ended June 30, 2022; amounts below are U.S. dollars.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $118.1M | $121.4M | $224.5M | $227.0M |
| Gross profit / margin | $86.5M / 73.2% | $94.0M / 77.4% | $164.6M / 73.3% | $173.6M / 76.5% |
| Operating income | $6.6M | $4.3M | $3.6M | $1.4M |
| Net income (loss) | $2.5M | $2.4M | ($2.0M) | ($3.4M) |
| Diluted EPS | $0.12 | $0.12 | ($0.10) | ($0.17) |
| EBITDA | $10.0M | $12.8M | $13.5M | $14.6M |
Q2 sales declined 2.7% reported, but were down only 0.5% at constant currency. Global Spine sales fell 4.1% reported (3.8% constant currency); Global Orthopedics grew 2.0% reported and 11.4% constant currency. For the first half, sales fell 1.1% reported but rose 0.7% constant currency.
Gross margin weakened as a result of sales mix, increased inventory reserves and safety stock, supply-chain-related component costs, and foreign exchange. Q2 sales and marketing expense rose 4.4% to $59.9M, partly reflecting resumed travel, events and added commercial staff. Q2 net income included a $10.7M reduction in acquisition-related expense from remeasurement of contingent consideration; this is a significant non-recurring factor in reported earnings.
Cash, liquidity and obligations
Cash and cash equivalents were $59.5M at June 30, 2022, down from $87.8M at year-end 2021. First-half operating cash flow was negative $12.6M versus positive $0.3M a year earlier; capital expenditures were $11.7M and reported free cash flow was negative $24.3M. The filing attributes cash-flow pressure in part to inventory growth and other working-capital movements. Inventory was $97.2M, up from $83.0M at year-end.
The company had no borrowings under its secured revolving facility or Italian credit lines and reported compliance with financial covenants. Finance lease liabilities totaled $20.2M; total lease liabilities, including operating leases, were $26.9M. Current assets were $255.2M and current liabilities $81.1M.
Management commentary, outlook and risks
Management cited hospital staffing constraints, patient caution around elective procedures and lower-than-expected complex spine procedure volumes as headwinds. It also noted competitive pressure in motion preservation, supply-chain disruption and cost inflation, and adverse currency movements. Management stated its cash, investments and revolving-credit access were expected to cover anticipated cash requirements; the filing provides no quantified revenue or earnings guidance.
Product and commercial developments included a limited launch of Virtuos Lyograft and partnerships with CGBio and LimaCorporate. The July 30, 2022 CGBio agreement grants U.S. and Canadian rights for Novosis rhBMP-2 and other regenerative solutions, for a $1.4M upfront payment plus milestone payments. The company also reported FDA approval of AccelStim in May, triggering $3.5M of IGEA-related consideration; $1.5M had been paid by June 30, with $2.0M remaining.
Contingencies include a $5.4M accrual for Italy’s medical-device payback measure, whose implementation remains uncertain. Spinal Kinetics has a remaining revenue milestone that may require a $30M payment if achieved by April 30, 2023; its recorded fair value was $1.0M, but the actual outcome is binary and may differ materially. The filing also identifies potential broader supply-chain, currency and logistics effects from the Russia-Ukraine conflict. Management said other legal matters were not expected to be material. Disclosure controls were assessed as effective at June 30, 2022.
Important facts for investors to verify
- Whether the $10.7M Q2 contingent-consideration remeasurement gain obscures underlying operating trends, and the probability of the remaining $30M Spinal Kinetics milestone.
- Whether inventory levels, gross margin and operating cash flow improve as supply constraints and elective-procedure activity evolve.
- The implementation and ultimate cost of Italy’s payback measure, and payment timing under the IGEA and CGBio agreements.
- Whether constant-currency growth in Global Orthopedics and new product initiatives translate into sustained reported sales and profitability.